脂肪来源干细胞外泌体用于糖尿病创面修复:分子交互、生物工程策略与转化挑战综述
原题:Adipose-Derived Stem Cell Exosomes in Diabetic Wound Repair: Molecular Crosstalk, Bioengineering Strategies, and Translational Challenges.
参考文献:Yao D, Xiao Y, Zhou M, Sun P, Wang L, Wang H.. Adipose-Derived Stem Cell Exosomes in Diabetic Wound Repair: Molecular Crosstalk, Bioengineering Strategies, and Translational Challenges. Europe PMC · 创面修复文献. 2026.
摘要
这篇综述以糖尿病创面病理到临床转化为框架,梳理脂肪来源干细胞外泌体(ADSC-Exos)的作用机制、工程化及递送策略,并将其定位为尚需临床验证的前临床平台。机制研究提示,ADSC-Exos可能通过调节巨噬细胞免疫代谢、促血管新生信号、细胞外基质稳态及角质形成细胞氧化损伤参与修复;工程化和生物材料递送可能改善局部滞留与控释。
展开来源摘要
Diabetic wounds are sustained by persistent inflammation, impaired angiogenesis, abnormal extracellular matrix (ECM) remodeling, and delayed re-epithelialization. Adipose-derived stem cell exosomes (ADSC-Exos) offer a cell-free strategy because their multicomponent cargo can modulate immune responses, vascular regeneration, fibroblast activity, and epidermal repair. Mechanistic studies suggest that ADSC-Exos promote macrophage immunometabolic reprogramming, restore pro-angiogenic signaling, improve matrix homeostasis, and protect keratinocytes from oxidative injury. Engineering approaches and biomaterial-based delivery systems may further improve local retention, controlled release, and therapeutic activity. Distinct from existing ADSC-Exos reviews, this review adopts a pathology-to-translation framework that connects the major pathological features of diabetic wounds with ADSC-Exos mechanisms, engineering strategies, delivery optimization, and clinical translation. Particular emphasis is placed on donor- and process-dependent heterogeneity, potency assessment, GMP-compatible manufacturing, biodistribution, long-term safety, and regulation. Overall, ADSC-Exos represent a mechanistically compelling preclinical platform, but clinical translation will require reproducible product quality, standardized potency criteria, scalable manufacturing, and rigorous clinical validation.